U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated…
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in…
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…
DAYTON, Ohio and CINCINNATI, June 25, 2025 /PRNewswire/ -- Independent creative strategy, branding, and experience design agency Hyperquake today announced…
Neuro-inspired Computation and Entrepreneurship Workshop Will Equip the Next Generation of Neuroscience Entrepreneurs with Foundational Tools for Startup Creation TOKYO,…
June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis…
Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costsNEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE…
To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat’s Phase III PORTICO-2 trial…
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive…
The Award Highlights the Promise of Exclusively Targeting Peripheral Opioid Receptors to Treat Chronic Pain Without the Risk of Addiction…